DK2927321T3 - Ch3-domæne-variantpar der inducerer dannelse af heterodimer af tungkæde konstant region af antistof ved høj effektivitet, fremgangsmåde til fremstilling af samme, og anvendelse deraf - Google Patents
Ch3-domæne-variantpar der inducerer dannelse af heterodimer af tungkæde konstant region af antistof ved høj effektivitet, fremgangsmåde til fremstilling af samme, og anvendelse deraf Download PDFInfo
- Publication number
- DK2927321T3 DK2927321T3 DK13859121.9T DK13859121T DK2927321T3 DK 2927321 T3 DK2927321 T3 DK 2927321T3 DK 13859121 T DK13859121 T DK 13859121T DK 2927321 T3 DK2927321 T3 DK 2927321T3
- Authority
- DK
- Denmark
- Prior art keywords
- heterodimes
- preparing
- heavy chain
- high efficiency
- constant region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120135586 | 2012-11-27 | ||
| PCT/KR2013/010861 WO2014084607A1 (ko) | 2012-11-27 | 2013-11-27 | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2927321T3 true DK2927321T3 (da) | 2021-03-15 |
Family
ID=50828165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13859121.9T DK2927321T3 (da) | 2012-11-27 | 2013-11-27 | Ch3-domæne-variantpar der inducerer dannelse af heterodimer af tungkæde konstant region af antistof ved høj effektivitet, fremgangsmåde til fremstilling af samme, og anvendelse deraf |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9951145B2 (da) |
| EP (2) | EP3878964A1 (da) |
| JP (1) | JP6385357B2 (da) |
| KR (1) | KR101522954B1 (da) |
| CN (1) | CN104955953B (da) |
| AU (1) | AU2013352812B2 (da) |
| CA (1) | CA2892623C (da) |
| DK (1) | DK2927321T3 (da) |
| EA (1) | EA032681B1 (da) |
| ES (1) | ES2861446T3 (da) |
| IL (1) | IL239041B (da) |
| WO (1) | WO2014084607A1 (da) |
Families Citing this family (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| EP3878964A1 (en) | 2012-11-27 | 2021-09-15 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| AU2014348552A1 (en) * | 2013-11-13 | 2016-06-02 | Zymeworks Inc. | Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2017004149A1 (en) * | 2015-06-30 | 2017-01-05 | Boehringer Ingelheim International Gmbh | Multi-specific binding proteins |
| US20170058052A1 (en) * | 2015-08-24 | 2017-03-02 | Trianni, Inc. | Enhanced production of immunoglobulins |
| KR101851380B1 (ko) | 2015-10-12 | 2018-04-23 | 아주대학교산학협력단 | 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍 |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| CN106883297B (zh) | 2015-12-16 | 2019-12-13 | 苏州康宁杰瑞生物科技有限公司 | 基于ch3结构域的异二聚体分子、其制备方法及用途 |
| US20190048064A1 (en) * | 2016-02-25 | 2019-02-14 | The Binding Site Group Limited | Antibodies |
| AU2017269115B2 (en) | 2016-05-26 | 2024-06-20 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
| SI3468586T1 (sl) | 2016-06-14 | 2025-01-31 | Xencor, Inc. | Bispecifična protitelesa za zaviralce kontrolnih točk |
| WO2018005706A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| EP3489262A4 (en) * | 2016-07-19 | 2020-07-08 | Ibentrus, Inc. | BISPECIFIC PROTEINS AND PROCESSES FOR THEIR PREPARATION |
| WO2018026942A1 (en) * | 2016-08-02 | 2018-02-08 | Merrimack Pharmaceuticals, Inc. | Heteromeric polypeptides |
| MX386014B (es) | 2016-08-10 | 2025-03-18 | Univ Ajou Ind Academic Coop Found | Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma. |
| WO2018030806A1 (ko) | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
| KR101928981B1 (ko) | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| IL268755B2 (en) | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| JP7556687B2 (ja) * | 2017-02-24 | 2024-09-26 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| AU2018250641B2 (en) | 2017-04-11 | 2025-03-13 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
| US20210017247A1 (en) | 2017-07-03 | 2021-01-21 | Torque Therapeutics, Inc. | Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof |
| CN111566214B (zh) * | 2017-07-06 | 2024-03-08 | 日东纺绩株式会社 | 抗人IgG4单克隆抗体及利用该抗体的人IgG4测定试剂 |
| CN111051350B (zh) * | 2017-09-07 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | 包含信号调节蛋白α的免疫缀合物 |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| CN109957026A (zh) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
| DK3728328T5 (da) | 2017-12-22 | 2025-02-17 | Argenx Bvba | Bispecifik antigenbindende konstruktion |
| EP3735254A4 (en) | 2018-01-05 | 2021-11-03 | City of Hope | MULTI-SPECIFIC LIGAND BINDERS |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| WO2019160007A1 (ja) | 2018-02-14 | 2019-08-22 | 中外製薬株式会社 | 抗原結合分子および組合せ |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| US20220025037A1 (en) * | 2018-04-03 | 2022-01-27 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting dll3, and use thereof |
| WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| BR112020020604A2 (pt) | 2018-04-11 | 2021-01-12 | Inhibrx, Inc. | Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| WO2020014542A2 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| US20210188957A1 (en) | 2018-08-29 | 2021-06-24 | Chugai Seiyaku Kabushiki Kaisha | Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-molecule |
| CA3115082A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| WO2020076992A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| WO2020138868A1 (ko) * | 2018-12-24 | 2020-07-02 | 서울대학교산학협력단 | 타입 1 인터페론 중화 fc-융합 단백질 및 이의 용도 |
| UA128825C2 (uk) | 2019-03-01 | 2024-10-30 | Ксенкор, Інк. | Гетеродимерні антитіла, що зв'язують enpp3 та cd3 |
| EP3959238A1 (en) * | 2019-04-25 | 2022-03-02 | F. Hoffmann-La Roche AG | Activatable therapeutic multispecific polypeptides with extended half-life |
| TWI911155B (zh) * | 2019-04-25 | 2026-01-11 | 瑞士商赫孚孟拉羅股份公司 | 藉由多肽鏈交換活化之治療性多特異性多肽 |
| TW202106714A (zh) * | 2019-04-25 | 2021-02-16 | 瑞士商赫孚孟拉羅股份公司 | 藉由多肽鏈交換製造抗體衍生之多肽 |
| WO2020243479A1 (en) | 2019-05-31 | 2020-12-03 | The Johns Hopkins University | Bispecific binding agents |
| EP4004026A4 (en) * | 2019-07-25 | 2023-11-15 | Trutino Biosciences Inc. | IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER |
| US20220411508A1 (en) * | 2019-09-09 | 2022-12-29 | The Regents Of The University Of California | Compositions and methods for making and using multispecific antibodies |
| EP4058150A2 (en) | 2019-11-15 | 2022-09-21 | Genzyme Corporation | Biparatopic cd73 antibodies |
| CN112898412A (zh) * | 2019-12-03 | 2021-06-04 | 复旦大学 | 一种高稳定性类Fab抗体及其制备方法和应用 |
| JP7738914B2 (ja) * | 2019-12-05 | 2025-09-16 | アーベル リミテッド | ＴｒｉＡｘ抗体の組成、その製造方法及び使用方法 |
| CA3165846A1 (en) | 2019-12-23 | 2021-07-01 | Denali Therapeutics Inc. | Progranulin variants |
| CN113121697B (zh) * | 2019-12-31 | 2023-06-09 | 周易 | Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用 |
| CN115380047A (zh) | 2020-01-29 | 2022-11-22 | 印希比股份有限公司 | Cd28单结构域抗体及其多价和多特异性构建体 |
| BR112022021625A2 (pt) | 2020-04-26 | 2022-12-06 | Biocytogen Pharmaceuticals Beijing Co Ltd | Imunoglobulinas modificadas |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| MX2022013663A (es) * | 2020-06-01 | 2022-11-30 | Mustbio Co Ltd | Anticuerpo biespecifico o fragmento de union a antigeno del mismo, y metodo de preparacion del mismo. |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| KR102697769B1 (ko) | 2020-09-14 | 2024-08-23 | 아주대학교산학협력단 | 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도 |
| KR20230118612A (ko) * | 2020-12-10 | 2023-08-11 | 인벤라 인코포레이티드 | 헤테로다이머화를 위한 직교 돌연변이 |
| EP4273161A4 (en) * | 2020-12-31 | 2025-04-02 | Innovent Biologics (Suzhou) Co., Ltd. | Protein with heterodimeric antibody FC and manufacturing method therefor |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| IL306074A (en) | 2021-03-24 | 2023-11-01 | Alkermes Inc | UPAR antibodies and fusion proteins with them |
| IL308183A (en) * | 2021-05-04 | 2024-01-01 | Regeneron Pharma | Multispecific FGF21 receptor agonists and their uses |
| JP2024527493A (ja) | 2021-06-16 | 2024-07-25 | アレクトル エルエルシー | 一価の抗ＭｅｒＴＫ抗体及びその使用方法 |
| US20240279341A1 (en) | 2021-06-16 | 2024-08-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| KR20230060546A (ko) | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| KR20240116743A (ko) * | 2021-11-09 | 2024-07-30 | 한양대학교 산학협력단 | Fc 변이체를 포함하는 이종이합체 및 이의 제조방법 |
| WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| CN116948029A (zh) * | 2022-04-20 | 2023-10-27 | 南京融捷康生物科技有限公司 | 一种包含IgG类Fc区变体的抗体及其用途 |
| KR102796245B1 (ko) | 2022-05-10 | 2025-04-18 | 아주대학교산학협력단 | 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도 |
| WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| US20240209100A1 (en) | 2022-10-21 | 2024-06-27 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| US20240383990A1 (en) | 2023-04-07 | 2024-11-21 | Diagonal Therapeutics Inc. | Hinge-modified bispecific antibodies |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
| WO2024219894A1 (ko) | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| KR102939282B1 (ko) | 2023-05-03 | 2026-03-16 | 아주대학교산학협력단 | IL-5Rα×CD3ε T 세포 관여 이중 특이 항체 및 이의 용도 |
| CN121219320A (zh) | 2023-05-19 | 2025-12-26 | 达科纳治疗有限公司 | 针对il12受体的双特异性激动性抗体 |
| WO2025007037A1 (en) | 2023-06-28 | 2025-01-02 | Dragonfly Therapeutics, Inc. | Variant il-2 proteins |
| WO2025038362A1 (en) | 2023-08-11 | 2025-02-20 | Merck Sharp & Dohme Llc | Monovalent interleukin 12 (il-12) heterodimeric fc proteins |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| AU2024366926A1 (en) | 2023-10-23 | 2026-03-12 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
| WO2025166077A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025166045A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| US20250388688A1 (en) | 2024-04-04 | 2025-12-25 | Ethyreal Bio, Inc. | Anti-tshr antibodies and uses thereof |
| WO2025240670A2 (en) | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anti-pd-1 antibodies and related binding molecules and methods and uses thereof |
| WO2025257408A1 (en) | 2024-06-14 | 2025-12-18 | Sanofi | Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| WO2026044000A1 (en) | 2024-08-20 | 2026-02-26 | Ethyreal Bio, Inc. | Multispecific antibodies and methods of use thereof |
| WO2026080748A2 (en) | 2024-10-09 | 2026-04-16 | Diagonal Therapeutics Inc. | Bone morphogenetic protein receptor type 2 (bmprii) antibodies |
| WO2026080752A2 (en) | 2024-10-09 | 2026-04-16 | Diagonal Therapeutics Inc. | De novo antibodies to activin a receptor like type 1 (alk1) |
| WO2026080757A2 (en) | 2024-10-09 | 2026-04-16 | Diagonal Therapeutics Inc. | Activin receptor type ii a/b (actriia/b) antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP2007536246A (ja) * | 2004-05-05 | 2007-12-13 | ジェネンテック・インコーポレーテッド | 自己免疫疾患の予防法 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| ES2563027T3 (es) * | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| US8067339B2 (en) | 2008-07-09 | 2011-11-29 | Merck Sharp & Dohme Corp. | Surface display of whole antibodies in eukaryotes |
| MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US9527926B2 (en) * | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| PL2635607T3 (pl) * | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| EP3878964A1 (en) | 2012-11-27 | 2021-09-15 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
-
2013
- 2013-11-27 EP EP21157452.0A patent/EP3878964A1/en active Pending
- 2013-11-27 AU AU2013352812A patent/AU2013352812B2/en active Active
- 2013-11-27 US US14/647,480 patent/US9951145B2/en active Active
- 2013-11-27 CA CA2892623A patent/CA2892623C/en active Active
- 2013-11-27 KR KR1020130145564A patent/KR101522954B1/ko active Active
- 2013-11-27 CN CN201380071306.XA patent/CN104955953B/zh active Active
- 2013-11-27 WO PCT/KR2013/010861 patent/WO2014084607A1/ko not_active Ceased
- 2013-11-27 JP JP2015543998A patent/JP6385357B2/ja active Active
- 2013-11-27 EA EA201591038A patent/EA032681B1/ru not_active IP Right Cessation
- 2013-11-27 DK DK13859121.9T patent/DK2927321T3/da active
- 2013-11-27 ES ES13859121T patent/ES2861446T3/es active Active
- 2013-11-27 EP EP13859121.9A patent/EP2927321B1/en active Active
-
2015
- 2015-05-27 IL IL239041A patent/IL239041B/en active IP Right Grant
-
2018
- 2018-04-03 US US15/944,505 patent/US11286311B2/en active Active
-
2021
- 2021-11-03 US US17/517,994 patent/US12344679B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015012310A2 (pt) | 2018-02-06 |
| CN104955953B (zh) | 2019-04-26 |
| JP6385357B2 (ja) | 2018-09-05 |
| US20180237541A1 (en) | 2018-08-23 |
| CA2892623C (en) | 2020-08-11 |
| EA201591038A1 (ru) | 2015-11-30 |
| EA032681B1 (ru) | 2019-07-31 |
| US9951145B2 (en) | 2018-04-24 |
| AU2013352812A1 (en) | 2015-07-16 |
| US12344679B2 (en) | 2025-07-01 |
| CN104955953A (zh) | 2015-09-30 |
| US20220162342A1 (en) | 2022-05-26 |
| EP2927321A4 (en) | 2016-06-15 |
| KR101522954B1 (ko) | 2015-05-27 |
| IL239041A0 (en) | 2015-07-30 |
| EP3878964A1 (en) | 2021-09-15 |
| JP2016506377A (ja) | 2016-03-03 |
| KR20140067944A (ko) | 2014-06-05 |
| WO2014084607A1 (ko) | 2014-06-05 |
| US20150307628A1 (en) | 2015-10-29 |
| ES2861446T3 (es) | 2021-10-06 |
| EP2927321A1 (en) | 2015-10-07 |
| CA2892623A1 (en) | 2014-06-05 |
| AU2013352812B2 (en) | 2019-06-20 |
| US11286311B2 (en) | 2022-03-29 |
| IL239041B (en) | 2019-06-30 |
| EP2927321B1 (en) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2927321T3 (da) | Ch3-domæne-variantpar der inducerer dannelse af heterodimer af tungkæde konstant region af antistof ved høj effektivitet, fremgangsmåde til fremstilling af samme, og anvendelse deraf | |
| DK3116305T3 (da) | Fremgangsmåder og sammensætninger til forøgelse af effektiviteten af målrettet genmodifikation ved anvendelse af oligonukleotidmedieret genreparation | |
| DK3221346T3 (da) | Antistoffer omfattende modificerede konstante områder af tungkæden | |
| DK3527068T3 (da) | Fremgangsmåder og sammensætninger til forøgelse af effektivitet af målrettet genmodifikation under anvendelse af oligonukleotid-medieret genreparation | |
| CL2018000370A1 (es) | Nuevos anticuerpos anti-pd-1 | |
| IL251563B (en) | Antibody molecules to pd-l1 and uses thereof | |
| IL248235B (en) | Method and compositions for cellular immunotherapy | |
| DK3828277T3 (da) | Sammensætninger, fremgangsmåder og apparatur til syntese af oligonukleotider | |
| DK2838917T3 (da) | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler | |
| DK3626081T3 (da) | Pasteuriseret akkermansia til fremme af vægttab | |
| DK3430141T3 (da) | Oligonukleotider til reduktion af PD-L1-ekspression | |
| PL3370768T3 (pl) | Przeciwciała specyficznie wiążące pd-1 i ich zastosowania | |
| DK3137091T3 (da) | Konjugater af modificerede antisense-oligonukleotider og anvendelse deraf til modulation af pkk-ekspression | |
| DK3334824T3 (da) | Pd-1-antistoffer | |
| PL3097121T3 (pl) | Cząsteczki przeciwciała przeciwko PD-1 i ich zastosowania | |
| CL2016002252A1 (es) | Anticuerpos anti-egfrviii y usos de los mismos | |
| DK3459965T3 (da) | Fremgangsmåder til forudsigelse af forfædrevirussekvenser og anvendelser deraf | |
| DK3473707T3 (da) | Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi | |
| DK2811876T4 (da) | Kaffemaskine og fremgangsmåde til betjening af samme | |
| DK3262071T3 (da) | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater | |
| DK3789042T3 (da) | Fremgangsmåde til fremstilling af anti-her3-antistof-lægemiddelkonjugat | |
| DK2884999T4 (da) | Fremgangsmåde og sammensætninger til cellulær immunterapi | |
| DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
| CO7151527A2 (es) | Anticuerpos anti-cd79 b e inmunoconjugados | |
| CL2016001742A1 (es) | Anticuerpos anti-baff novedosos |